Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by barcodewhizon Aug 18, 2006 10:42am
180 Views
Post# 11243514

HMSL etc

HMSL etc From what I can gather, the mediation judge has roughly two weeks to present his judgement. My gut feeling that we are going to get some kind of definitive resolution that will finally get rid of this overhang and move us in a positive direction. We have been expecting this for far too long and it has frustrated us longtimers and the market..... so much so, that many regularls pulled the plug once and for all. I am using this window as an opportunity to increase my position. I think a new and properly funded Hemosol with a definitive strategy and direction will be a boost to Prometic and the PPPS technology. I have been saying over and over again that a key for Prometic's success is to attract and keep a solid institutional following. Melnyk's track record with Biovail and his substantial personal wealth and institutional following could bring exactly that, especially if he makes a big enough splash with Hemosol and its potential. Thinking out a little further, it isnt even too far fetched to see HMSL and PLI being an attractive aquisition package for the right buyer. If you believe that the UK IPO is imminent in conjunction with a CE Mark announcement and product launch, then we very well might get some badly needed positive momentum. 1402 is the wildcard that could amplify any move. I know we have all been unbelievably patient... and largely WRONG for hanging on as long as we have.... but I do honestly feel like we are setup for our long awaited payback if the company can definitely put a couple of these catalysts behind it
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse